The management of T1G3 bladder cancer

Urologia Internationalis

Volumn 69, Issue 4, 2002, Pages 263-265

  Bogdanović, Jovo ^a,c   Marušić, Goran ^a   Djozić, Jasenko ^a   Sekulić, Vuk ^a   Budakov, Pavle ^b   Dejanović, Nebojša ^a   Stojkov, Jovan ^a  

^a Clinic of Urology

^b Clinical Center Novi Sad   (SCG)

^c Clinical Center of Novi Sad   (Yugoslavia)

Author keywords

BCG immunotherapy, management; High risk superficial bladder cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CONVALESCENCE; CYSTECTOMY; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; BLADDER TUMOR; CANCER STAGING; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 0036441480     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066121     Document Type: Article

References (15)

1. Herr HW: Tumour progression and survival in patients with T1G3 bladder tumours: 15-Year outcome. Br J Urol 1997;80:762-765.
2. Eure GR, Cundiff MR, Schellhammer PF: Bacillus Calmette-Guérin therapy for high-risk stage T1 superficial bladder cancer. J Urol 1992;147:376-379.
3. Cookson MS, Sarosdy MF: Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy. J Urol 1992;148:797-801.
4. Pansadoro V, Emiliozzi P, Defidio L, Donadio D, Florio A, Maurelli S, Lauretti S, Sternberg CN: Bacillus Calmette-Guérin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: Long-term results. J Urol 1995;154:2054-2058.
5. Otto T, Rubben H: Management of T1GIII bladder tumours. Eur Urol Update Ser 1994;3:122-125.
6. Smitz-Dräger BJ, Müller M: Intravesical treatment of bladder cancer: Current problems and needs. Urol Int 1998;61:199-205.
7. Lamm DL, Blumenstein BA, Crawford ED, Montie JF, Scardino P, Grossman HB, Stanisic TH, Smith JA, Sullivan J, Sarosdy MF, Crissman JD, Coltman CA: A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991;325:1205-1209.
8. Bono AV, Lovisolo JA, Saredi G: Transurethral resection and sequential chemoimmunoprophylaxis in primary T1G3 bladder cancer. Eur Urol 2000;37:478-483.
9. Amling CL, Thrasher JB, Fraiyer HA, Dodge RK, Robertson JE, Paulson DF: Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 1994;151:31-35.
10. Zungri E, Martinez L, Da Silva EA, Pesqueria D, de la Fuente Bucetta A, Pereior B: T1GIII bladder cancer management with transurethral resection only. Eur Urol 1999;36:380-385.
11. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H: Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: Recurrence, progression and success. Eur Urol 1998;34:67-72.
12. Baniel J, Grauss D, Engelstein D, Sella A: Intravesical bacillus Calmette-Guérin treatment for stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998;52:785-789.
13. Brake M, Loertzer H, Horsch R, Keller H: Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guérin. J Urol 2000;163:1697-1701.
14. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A: Low-dose Pasteur bacillus Calmette-Guérin regimen in stage T1, grade 3 bladder cancer therapy. J Urol 1996;156:1602-1605.
15. Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, Simon J, Schulman CC: Correlation and prognostic significance of p53, p21 WAFI/CIPI and Ki67 expression in patients with superficial bladder tumours treated with bacillus Calmette-Guérin intravesical therapy. J Urol 1999;161:792-798.